News Desk:: Johnson & Johnson’s single-shot COVID vaccine has been recommended for conditional approval by the EU drugs regulator.
The European Medicines Agency (EMA) said it should only be recommended for over-18s.
Authorisation for the vaccine will follow shortly, said the EU Commission.
The bloc has had a slow start in rolling out vaccines, with its president criticised for not acting fast enough.
The Johnson & Johnson jab is the fourth to be endorsed for use in the European Union after those from Pfizer, AstraZeneca and Moderna.
America, Canada and Bahrain have also signed if off, while South Africa is doing an expedited review.
The UK has ordered 30 million doses, pending approval by the Medicines and Healthcare products Regulatory Agency (MHRA), with the option of millions more.
In a 44,000-person global trial carried out by Johnson & Johnson, the vaccine was found to be 66% effective at preventing moderate-to-severe COVID-19 four weeks after inoculation.
It was 100% effective in preventing hospitalisation and death due to the virus.
As well as being one shot, it also only needs to be kept at fridge temperature, making its storage, distribution and handling much easier.
And costing as little as $10 (£7) a dose, it is cheaper than most vaccines – coming in at about the same as two shots of the Oxford/AstraZeneca option.
Johnson & Johnson also said it worked across multiple variants of coronavirus, including the South African variant.
Bangladesh’s coronavirus caseload surges by 100,000 in 16 days